Although Agios and Celgene are set to file for approval for their first-in-class cancer metabolism drug, the field has started looking in new directions for the next batch of metabolic targets.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Mullard, A. Cancer metabolism pipeline breaks new ground. Nat Rev Drug Discov 15, 735–737 (2016). https://doi.org/10.1038/nrd.2016.223
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd.2016.223
This article is cited by
-
Modeling and Simulation in Biomedical Engineering: Regulatory Science and Innovation for Advancing Public Health
Annals of Biomedical Engineering (2023)
-
TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress
Communications Biology (2022)
-
How previous treatment changes the metabolomic profile in patients with metastatic breast cancer
Archives of Gynecology and Obstetrics (2022)
-
Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers
Journal of Experimental & Clinical Cancer Research (2021)
-
Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis
Nature Communications (2021)
